Valve in Valve Presents Better Evolution than re-SARV

Courtesy of Dr. Carlos Fava.

Surgical aortic valve replacement with bioprosthesis has proved its benefits, but it fails after 10 to 15 years. 

valve_in_valve-compressor

Transcatheter aortic valve replacement has been shown valid, especially in high risk patients, but we still have little information and no “head to head” studies to know what is best in this group that keeps growing over the years. 

A retrospective analyzis of the National Readmissions Database (NRD) from 2012 to 2016 was carried out, including 6815 procedures, 3443 (50.5%) receiving V-in-V TAVI and 3372 re-SAVR.

The V-in-V TAVR group had older patients, with prior CABG, kidney function deterioration and cardiac failure. 

At 30 days, this population had lower mortality (2.8% vs. 5.0%; OR 0.55, 95% CI 0.33 – 1.91), morbidity (66.4% vs. 79%; OR 0.52, 95% CI 0.41 – 0.66) and major bleeding (35.8% vs. 49.9%; OR 0.56, 95% CI 0.44 – 0.71). In addition, it presented shorter hospital stay (7 vs. 9 days, on average 2 days, 95% CI 1.4 – 2.6) and higher home discharge (45.9% vs. 34.2%; OR 1.57, 95% CI 1.28 – 1.93).


Read also: EuroPCR 2020 | Aortic Valve in Valve in the Long Term.


There were no differences in stroke, kidney failure, need for pacemaker, A-V block or cost between procedures. Likewise, there were no differences in rehospitalization need within 30 days. 

On multivariable analyzis, the re-SAVR group was associated with higher mortality and morbidity and 30’ days.

When comparing groups, propensity score matching left 2181 pairs. 


Read also: Is V-in-V the Treatment of Choice in Cases of Failed Biological Prosthesis?


At 30 day followup, V-in-V TAVR was associated to lower mortality (OR 0.41, 95% CI 0.23–0.74), lower morbidity (OR 0.53, 95% CI 0.43–0.72), lower major bleeding (OR 0.66, 95% CI 0.51–0.85), shorter hospital stay (on average two days 95% CI 1.3–2.7) and higher discharge (OR 2.11, 95% CI 1.61–2.78) compared against re-SAVR.

Patients undergoing re-SAVR had 59% more mortality, 63% morbidity and 71% major bleeding. Patients in the V-in-V TAVR group showed 3.9 more chances of home discharge compared against re-SAVR patients.

Conclusion

In this study of high-risk population with bioprosthetic aortic valve failure, V-in-V TAVR seems to have an advantage over re-SAVR at 30 days in terms of mortality, morbidity, and major bleeding.

Further study is necessary in low, intermediate, and high-risk patients to look into long term effectiveness. 

Gentileza del Dr. Carlos Fava.

Original Title: Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world outcomes.

Reference: Sameer A. Hirji, et al. European Heart Journal (2020) 0, 1–9. doi:10.1093/eurheartj/ehaa252.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...